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Implantable cardioverter deﬁbrillator (ICD) therapy is com-
monly used for the prevention of sudden arrhythmic death in
high risk populations. A recognized complication of such
therapy is lead failure, leading to potential inappropriate
detection and delivery of high energy deﬁbrillation shocks.
Many modern devices utilize algorithms which can differ-
entiate between lead noise and true arrhythmia, avoiding
unnecessary therapies. However, the programming of these
algorithms can be the difference between life and death.
Below is presented a case of lead failure in which the default
programming of the device’s algorithms contributed to a
catastrophic outcome which was potentially avoidable.Case report
A 31-year-old male patient was admitted to the hospital with
severe heart failure and cardiogenic shock in the setting of
amphetamine-induced dilated cardiomyopathy and an ejection
fraction (EF) of 5%–10%. After 10 weeks of in-hospital care
with the administration of diuretics, inotropes, and intra-aortic
balloon counterpulsation and the optimization of medications,
his condition stabilized. However, his left ventricular (LV)
systolic function remained severely impaired, with an EF of
approximately 10%. As a consequence, he received a Protecta
VR (Medtronic Corporation, Minneapolis, MN) single-KEYWORDS Deﬁbrillator; Ventricular ﬁbrillation; ICD therapy; Sudden death;
Lead fracture
ABBREVIATIONS ATP¼ antitachycardia pacing; bpm¼ beats per minute;
EF ¼ ejection fraction; EGM ¼ electrogram; ICD ¼ implantable
cardioverter defibrillator; LV ¼ left ventricle; RV ¼ right ventricle;
RVLND ¼ right ventricular lead noise discrimination; SVC ¼ superior
vena cava; TWOS ¼ T-wave oversensing; VF ¼ ventricular fibrillation;
VT ¼ ventricular tachycardia (Heart Rhythm Case Reports 2016;2:6–10)
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Minneapolis, MN) dual-coil lead prior to discharge. At the
implantation of the device, the R-wave amplitude was 7.5 mV,
the pacing threshold was 0.9 V at 0.4 milliseconds, and the
pacing impedance was 784 ohms. The high-voltage lead
impedance was 68 ohms through the right ventricular (RV)
coil and 61 ohms through the superior vena cava (SVC) coil.
Deﬁbrillation testing was not performed, because of the
presence of an LV apical thrombus in the preceding month
and relative hemodynamic instability at the time of implanta-
tion. The device was programmed to detect ventricular
ﬁbrillation (VF) at rates 4200 beats per minute (bpm), and
the therapy to be delivered was a maximum of 6 35-J shocks
with antitachycardia pacing (ATP) during charging. Alerts were
programmed for RV lead integrity and RV lead noise, for RV
pacing lead impedance out of range (o200 or43000 ohms),
and for RV and SVC deﬁbrillation lead impedance out of range
(o20 or 4200 ohms). ‘RV lead noise discrimination’
(RVLND) was also programmed ‘on’ (by default) with an
’RV lead noise timeout’ at the default value of 0.75 minute (see
the Discussion section for further details).
A signiﬁcant clinical improvement was noted, and the
patient returned to work some months later. At heart failure
clinic follow-up, LV EF had improved to 15%–20%, and he
was walking up to a mile a day. Medical therapy was
continually titrated until he was on optimal doses of beta-
blockade, angiotensin-converting enzyme inhibitor, and
aldosterone antagonist. The patient missed an ICD follow-
up appointment 6 months post implant and was subsequently
lost to ICD follow-up.
Three years after initial presentation, the patient died
suddenly and unexpectedly, despite feeling well and having
no symptoms when he was last seen, 30 minutes prior to his
death. Postmortem interrogation of his explanted ICD
demonstrated an abrupt failure of his RV pace-sense lead,
with an abrupt rise in RV pace-sense lead impedance on the
day of the patient’s death. The impedance change was
associated with detection of noise beginning with short
(1 second) episodes of noise just 1 hour 53 minutes beforepen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.07.004
KEY TEACHING POINTS
 Inappropriate ICD therapies due to lead noise can
be fatal.
 Lead noise-discrimination algorithms have the
ability to detect lead noise and withhold high-
voltage therapies, but this function is limited by
preprogrammed time-outs. These time-outs can be
manually extended or disabled by the clinician.
Such programming can be the difference between
life and death (as in this case).
 Postmortem ICD interrogation should be indicated
in cases of sudden unexplained death in an ICD
recipient, as catastrophic system failures may be
highlighted.
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were noted shortly after the episode began. The duration of
the noise episodes increased over the intervening period. The
device transiently suppressed VF detection by recognizing
the high rates as being noise (Figure 1) and due to the default
time-out in the RVLND algorithm, VF would have been
detected after 45 seconds of persistent noise. However, VF
was actually detected after 8 seconds because of an
interaction between the T Wave Discrimination algorithm
and the RVLND algorithm, resulting in an even shorter
suspension of VF detection, to only 8 seconds. The ICD
proceeded to deliver a sequence of maximum output 35-J
shocks, the third of which induced true VF (Figure 2). Three
subsequent shocks failed to terminate the VF (Figure 3), and
therapy was automatically discontinued, leaving the patient
in VF from which he was not resuscitated.
Discussion
Inappropriate shocks are an unwelcome and potentially life-
threatening complication of ICD therapy.1 Recent advancesFigure 1 Initial right ventricular lead noise discrimination algorithm (RVLND
reveals a stable intrinsic rate.have dramatically reduced inappropriate shocks due to
supraventricular arrhythmias.2 Inappropriate shocks due to
lead fracture or insulation break can be more difﬁcult
to prevent, particularly when lead failure is abrupt. The
incidence of such events may be underestimated due to a
relative paucity of postmortem ICD interrogations, even in
cases of unexplained sudden death in ICD recipients.3 While
such sudden deaths are often assumed to be spontaneous
arrhythmic deaths, possibly with failure of ICD shocks to
terminate episodes, the possibility of episodes being caused
by the ICD is rarely considered.
ICD lead fractures may result in failure of detection and
therapy delivery as well as lead noise that can result in
unnecessary therapy delivery. The failure rate for Sprint
Quattro leads has been shown to be 0.43% per year in a
multicenter study.4 Many modern devices have incorporated
features to detect noise and avoid inappropriate shocks, but
the utility of lead noise-detection algorithms with suppres-
sion of tachyarrhythmia detection may be limited by their
preprogrammed time-outs.
In this case, the patient had the quadruple misfortune of
these events:1.) inhAn abrupt lead fracture with immediate sensing of noise
2. Failure of the RVLND algorithm to prevent detection of
VF
3. Induction of VF by one of the resulting shocks
4. Failure to deﬁbrillate by 3 subsequent shocks, despite the
fact that charge times, high voltage impedance, and
delivered energy were all appropriate or normal
Although the alarms were programmed ‘on,’ the abrupt-
ness of lead failure made it extremely unlikely that the
patient would have enough time to seek help in response to a
device alarm.
The Medtronic RVLND algorithm differentiates RV lead
noise from VT or VF by comparing a far-ﬁeld electrogram
(EGM) signal to near-ﬁeld sensing.5 The algorithm instructsibiting therapy due to detection of noise (N). The far-ﬁeld electrogram
Figure 2 The third high-voltage therapy (red box) caused the patient’s intrinsic rate to accelerate to a high-frequency (ventricular ﬁbrillation [VF]) rate, which
is clearly visible in the far-ﬁeld can to right ventricular coil electrogram.
Heart Rhythm Case Reports, Vol 2, No 1, January 20168the device to withhold detection and therapy for ventricular
rates of4200 bpm in the near-ﬁeld (RVtip to RVring bipole)
electrogram (EGM) when there is signiﬁcant discordance
with the far-ﬁeld (RV coil to can) EGM. The RV lead noise
time-out function determines the duration for which detec-
tion and therapy is withheld. With the nominal programming
conﬁguration for this device, if oversensing persists for 45
seconds, the RVLND algorithm will stop withholding
detection because of the preprogrammed time-out. This
event would lead to subsequent detection and initiation of
therapy if the oversensing persists. RVLND time-out is
nominally programmed ‘on’ with a time-out of 45 seconds
because approximately 88% of the lead noise episodes last
o45 seconds.6 This time-out can be programmed to up to
120 seconds and may be programmed ‘off,’ which allows the
device to withhold detection and therapy indeﬁnitely in the
setting of lead noise. This function is incorporated into the
Medtronic Protecta, Evera, and Viva devices.5
Information from lead impedance, pacing threshold, and
R-wave size are not incorporated into the algorithm.5
RVLND has both an audible alert and a programmableFigure 3 The fourth high-voltage therapy fawireless CareAlert, which is transmitted to CareLink if
applicable. The audible alert continues to sound at regular
intervals until the device is interrogated.5
Other manufacturers have similar but different algorithms.
The St Jude Medical SecureSense algorithm is similar to the
Medtronic RVLND algorithmwith a comparison of the number
of sensed signals between near- and far-ﬁeld bipoles.7 If the
near-ﬁeld signal count is 10 greater than the far-ﬁeld signal by
the time of detection, therapy will be withheld. The St Jude
Medical SecureSense algorithm can withhold therapy indef-
initely, and the time-out is nominally programmed ‘off.’7 It is
possible that such a conﬁguration could have led to VF
detection being withheld indeﬁnitely in a case such as this.
Boston Scientiﬁc have incorporated a Dynamic Noise
algorithm that resets the sensing threshold when high-
frequency, nonphysiological, low-amplitude signals are
detected.8 According to Boston Scientiﬁc engineers, this
algorithm is primarily used to detect external electromag-
netic interference and is unlikely to have been effective in
detecting high-amplitude noise, as in this case (written
communication, July 1, 2014).iled to terminate ventricular ﬁbrillation.
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ADþ algorithms10 are primarily focused on discrimination
between supraventricular arrhythmias and ventricular
arrhythmias and would have been unlikely to have prevented
VF detection and therapy in this case, as they are not
designed to detect lead noise.
Another contributory feature to this event was the
interaction between the TWave Discrimination and RVLND
algorithms. As part of the Medtronic SmartShock Tech-
nology, the T Wave Discrimination algorithm was given
precedence over the RVLND algorithm. According to
Medtronic engineers, this feature was included to prevent
unnecessary lead noise alerts caused by large near-ﬁeld T
waves corresponding to small far-ﬁeld T waves (written
communication, May 1, 2015). An unforeseen complication
of this strategy was that ﬂeeting recognition of T-wave
oversensing (TWOS) during lead noise episodes inhibits
RVLND processing. This interaction means that VF detec-
tion can occur despite lead noise having been recognized.
This interaction has been recognized by the manufacturer,
and all devices that have undergone a routine ICD inter-
rogation since mid-2013 have had this interaction removed
via a RAMware download. The RAMware download
removes the speciﬁc interaction so that ﬂeeting recognition
of TWOS cannot inhibit RVLND. This change has also been
incorporated into the more recent line of Medtronic devices
that have SmartShock Technology 2.0. However, devices
that have not undergone a routine interrogation since mid-
2013 may still have this interaction present. In this case, the
interaction allowed VF detection to occur sooner than the
preprogrammed time-out, but this phenomenon is unlikely to
have changed the outcome, as the period of lead noise was
sustained for 415 minutes and VF would have been
detected after 45 seconds if the interaction had not been
present.
Reﬁnements in current noise-detection algorithms
are needed to prevent a recurrence of this type of case.
A potential strategy may be to use the time-out as an
opportunity to check lead and coil impedance and compare
them with previous measurements. If there has been a
sudden, prespeciﬁed change in these parameters and persis-
tent discordance between near-ﬁeld and far-ﬁeld electro-
grams, then high ventricular rates detected can be assumed to
be due to lead noise resulting from mechanical damage to the
lead or its components.11 In fact, the Medtronic lead integrity
alert already uses short intervals and impedance changes to
warn of likely lead or connector problems.5 In this circum-
stance, therapy could be withheld indeﬁnitely with immedi-
ate and frequent sounding of a ‘maximum loudness alarm,’
possibly with an audio prompt to seek immediate medical
attention. Frequent transtelephonic ICD interrogation may
not be enough to protect patients from acute lead failure in
these circumstances. Instant or near-instant loud warning
alarms in cases of sudden onset, heavy burdens of lead noise
may need to be developed.
Another issue that is highlighted by this case is the lack of
routine postmortem ICD interrogation in cases of suddencardiac death. Pacemakers and ICDs are routinely explanted
postmortem in many countries, particularly if cremation is
planned. Postmortem ICD interrogation can help determine
the cause of death (eg, ventricular tachyarrhythmias) and
evaluate product reliability and malfunctions that may have
contributed to a patient’s death.12
A strong case can be made for mandatory postmortem
interrogation of ICDs in the case of sudden death in ICD
recipients. In this case, the ICD was interrogated postexplant,
but the diagnosis of possible lead fracture was made at a time
that was too late to allow inspection of the leads. In cases of
abrupt lead failure, a postmortem chest radiograph could
identify the site of lead fracture and should be considered.
Potential strategies for improving ICD handling of lead
noise include the following: ICD manufacturers adapt the noise-detection algorithms
on their devices to recognize signiﬁcant excess counts on
near-ﬁeld compared to far-ﬁeld channels as noise. In such cases, RV impedances could be checked prior to
time-out of noise detection. Have an indeﬁnite time-out if RV pacing lead impedance
has changed signiﬁcantly. Develop new high-volume alarms for such life-
threatening situations.
Conclusions
ICDs have been a major advance in the prevention of sudden
cardiac death in selected high-risk populations. Noise-
discrimination algorithms can avoid inappropriate therapies,
but their utility is limited by their preprogrammed time-outs.
Cases such as this demonstrate that an unexplained sudden
cardiac death indicates mandatory postmortem interrogation
of the ICD rather than burying the evidence.
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